Document is current
Any future updates will be listed below
-
Authors
Khan, Kabir A https://orcid.org/0000-0001-8453-3485
Wu, Florence TH https://orcid.org/0000-0002-6439-4606
Cruz‐Munoz, William
Kerbel, Robert S https://orcid.org/0000-0002-6015-2570
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT 148542)
Canadian Cancer Society
Worldwide Cancer Research (14‐1329)
University of Toronto
CIHR Banting Postdoctoral Fellowship
- License Information
-
More Information
Article History
Received: 12 July 2017
Revised: 10 March 2021
Accepted: 11 March 2021
First Online: 14 June 2021
Conflict of interest
: RSK is a member of the Scientific Advisory Board of Angiocrine Bioscience Inc., CSTS Healthcare, Novelty Nobility, Nonagen Therapeutics and OncoHost and a consultant to Novelty Nobility, Pharmabcine, and CSTS Healthcare. The other authors declare no conflicts of interest.
